Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: drug pricing

ACR Expresses Concerns with MedPAC’s Drug Pricing Recommendations

From the College  |  May 9, 2023

In April, the Medicare Payment Advisory Committee voted to recommend a change in the add-on payment for Part B drugs, including reducing payment for more expensive drugs. The ACR sent a letter to MedPAC expressing concerns about the significant impacts such policies would have on rheumatologists.

Filed under:Legislation & Advocacy Tagged with:ACR advocacydrug pricingMedicare Part B drugs

Florida Law Puts Drug Pricing by Pharmacy Benefit Managers Under a Microscope Once Again

Catherine Kolonko  |  August 8, 2022

As of July 1, a Florida bill increases oversight of pharmacy benefit managers and offers some protection for pharmacies. However, the legislation has limited effects on patients and providers, highlighting the need for additional reform.

Filed under:Legislation & Advocacy Tagged with:Floridapharmacy benefit managers (PBMs)state legislation

RheumPAC Donors Discuss Healthcare Legislation, Drug Pricing with Rep. Lloyd Doggett

Zach Wallace, MD, MSc  |  May 7, 2021

At a virtual event with the chair of the Ways & Means Subcommittee on Health, RheumPAC donors were able to share concerns and recommendations about drug pricing policies and how they affect providers and patients.

Filed under:American College of RheumatologyLegislation & Advocacy Tagged with:Legislation & AdvocacyLloyd DoggettRheumPAC

Drug Pricing Bills Move Forward

Angus Worthing, MD, FACP, FACR  |  September 20, 2019

This week, the U.S. House of Representatives released a long-anticipated plan that contains provisions to reduce U.S. drug prices according to an international price index.

Filed under:Drug Updates Tagged with:drug pricingLegislation

Making Sense of Drug Pricing Legislation

From the College  |  July 2, 2019

A number of bills have been introduced in the 116th Congress to mitigate the impact of treatment and drug costs on U.S. patients. The ACR has reviewed the bills and supports those that most closely align with its positions on access to care.

Filed under:Drug UpdatesLegislation & AdvocacyProfessional Topics Tagged with:AdvocacyAmerican College of Rheumatology (ACR)drugLegislationrheumatology

WHO Drug Pricing Talks May Fail to End Secrecy, Activists Fear

Tom Miles  |  May 26, 2019

GENEVA (Reuters)—Governments are working on a drug pricing transparency deal at the World Health Organization’s (WHO) annual assembly, but activists said on Thursday they fear crucial costs may be left out, enabling pharmaceutical firms to keep prices high. Campaigners say some drugs are exhorbitantly priced, even though they are often developed with public funding, and…

Filed under:Drug Updates Tagged with:drug pricing transparencydrug pricing transparency dealpharmaceutical industryWorld Health Organization (WHO)

U.S. Lawmaker Launches Investigation into Pharma Drug Pricing

Yasmeen Abutaleb  |  January 15, 2019

WASHINGTON (Reuters)—A top U.S. lawmaker has launched an investigation into pharmaceutical industry pricing practices, less than a week after he and fellow Democrats introduced legislation aimed at lowering medicine prices. Rep. Elijah Cummings (D-Md.), who chairs the U.S. House Oversight Committee, sent letters to 12 drug makers seeking information on price increases, investment in research…

Filed under:Drug Updates Tagged with:costsdrug costdrug cost legislationU.S. Congressional Budget Office

ACR Responds to Drug Pricing Proposals

Mary Beth Nierengarten  |  June 21, 2018

Responding to the Trump administration’s drug pricing proposals, the ACR released a set of principles it hopes will help guide any drug policy changes.1 The principles underscore what is critically needed for rheumatologists to provide the best and safest care to their patients, many of whom require ongoing treatment for chronic conditions. “The ACR has…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:ACR principlesAmerican Patients First Drug Pricing Blueprintdrug policy changesTrump administration’s drug pricing proposals

ACR/ARHP Visits the Hill; Drug Pricing ‘Blueprint’ Revealed

Angus Worthing  |  June 8, 2018

Greetings, Advocates! In my last update, I described the great news from February’s budget agreement that fixed Medicare’s payment adjustments so MIPS penalties would not include Part B drug costs, ensuring stabilization of the Medicare Part B drug system, among other successes. (Read the ACR’s press release on this topic.) I also described the Trump administration’s…

Filed under:American College of RheumatologyLegislation & Advocacy Tagged with:Association of Rheumatology Professionals (ARP)Biosimilarsdrug pricesfly-inWashington D.C. update

ACR Leads Coalition Response to HHS Proposed Drug Pricing Threats

Carina Stanton  |  April 20, 2018

Potential federal drug pricing proposals could shuffle Part B drug coverage into the Part D program and restructure reimbursements for new drugs, moves that would jeopardize patient access to care, explains Kent “Kwas” Huston, MD, a rheumatologist in Kansas City, Mo., and a member of the ACR’s Government Affairs Committee (GAC). “We believe Part D…

Filed under:Legislation & Advocacy Tagged with:coalition responseHHSKent “Kwas” HustonPart B drug coverageproposed drug pricing threatsrestructure reimbursements

  • 1
  • 2
  • 3
  • …
  • 22
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences